OSRC
MCID: OST159
MIFTS: 66

Osteogenic Sarcoma (OSRC)

Categories: Bone diseases, Cancer diseases, Genetic diseases, Rare diseases

Aliases & Classifications for Osteogenic Sarcoma

MalaCards integrated aliases for Osteogenic Sarcoma:

Name: Osteogenic Sarcoma 57 12 76 53 59 75 15
Osteosarcoma 57 12 53 59 75 37 29 13 55 6 44 15 40 73
Neoplasms, Bone Tissue 44 73
Osrc 57 75
Osteosarcoma, Somatic 57
Bone Tissue Neoplasm 12
Osteosarcoma of Bone 73
Osteosarcoma; Osrc 57
Skeletal Sarcoma 12
Osteoid Sarcoma 12
Bone Sarcoma 73

Characteristics:

Orphanet epidemiological data:

59
osteosarcoma
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe); Age of onset: Childhood;

OMIM:

57
Inheritance:
? autosomal recessive


Classifications:

Orphanet: 59  
Rare bone diseases


External Ids:

OMIM 57 259500
Disease Ontology 12 DOID:3347
NCIt 50 C9145
SNOMED-CT 68 21708004
Orphanet 59 ORPHA668
MESH via Orphanet 45 D012516
ICD10 via Orphanet 34 C41.9
UMLS via Orphanet 74 C0029463
MedGen 42 C0029463
KEGG 37 H00036

Summaries for Osteogenic Sarcoma

NIH Rare Diseases : 53 Osteosarcoma is the most common type of bone cancer. The average age at diagnosis is 15. Boys and girls have a similar incidence of this tumor until late adolescence, at which time boys are more commonly affected. In rare cases, osteosarcoma occurs in adults. Although osteosarcoma tends to occur in the larger bones, such as the shin (near the knee), thigh (near the knee) and upper arm (near the shoulder), it can occur in any bone.A number of variants of osteosarcoma exist, including conventional types (osteoblastic, chondroblastic, and fibroblastic), telangiectatic, multifocal, parosteal, and periosteal. The cause of osteosarcoma is not known. In some cases, it runs in families, and at least one gene has been linked to increased risk. Treatment varies from person to person and may include surgery, chemotherapy, radiation therapy, and samarium.

MalaCards based summary : Osteogenic Sarcoma, also known as osteosarcoma, is related to lung cancer susceptibility 3 and retinoblastoma. An important gene associated with Osteogenic Sarcoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Human T-cell leukemia virus 1 infection and p53 Signaling. The drugs Fusilev and Lithium carbonate have been mentioned in the context of this disorder. Affiliated tissues include bone, lung and breast, and related phenotypes are fever and joint swelling

Disease Ontology : 12 A bone cancer that is located in bone that has material basis in cells of mesenchymal origin.

UniProtKB/Swiss-Prot : 75 Osteogenic sarcoma: A sarcoma originating in bone-forming cells, affecting the ends of long bones.

Wikipedia : 76 An osteosarcoma (OS) or osteogenic sarcoma (OGS) is a cancerous tumor in a bone. Specifically, it is an... more...

Description from OMIM: 259500

Related Diseases for Osteogenic Sarcoma

Diseases related to Osteogenic Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 399)
# Related Disease Score Top Affiliating Genes
1 lung cancer susceptibility 3 31.1 AKT1 FENDRR HOTAIR MALAT1 TP53 TUG1
2 retinoblastoma 31.0 HOTAIR MALAT1 RB1 TP53
3 adenocarcinoma 30.6 AKT1 MALAT1 RB1 TP53
4 li-fraumeni syndrome 2 30.5 CHEK2 TP53
5 glioma 30.5 HOTAIR MALAT1 MIR140 NEAT1 TP53
6 squamous cell carcinoma 30.3 AKT1 CHEK2 HOTAIR MALAT1 NEAT1 RB1
7 nasopharyngeal carcinoma 30.3 AKT1 HOTAIR MALAT1 NEAT1 TP53
8 renal cell carcinoma, nonpapillary 30.1 DANCR HOTAIR MALAT1 TUG1
9 breast cancer 29.9 AKT1 BCAR4 CHEK2 DANCR FOXC2-AS1 HOTAIR
10 colorectal cancer 29.9 AKT1 BCAR4 CHEK2 DANCR HOTAIR MALAT1
11 prostate cancer 29.9 AKT1 CHEK2 DANCR FENDRR HOTAIR MALAT1
12 b-cell lymphomas 29.9 HOTAIR MALAT1 TP53 TUG1
13 lung cancer 29.9 AKT1 BCAR4 CHEK2 DANCR FENDRR HOTAIR
14 small cell cancer of the lung 29.9 AKT1 HOTAIR MALAT1 RB1 TP53 TUG1
15 cholangiocarcinoma 29.9 AKT1 MALAT1 NEAT1 TP53 TUG1
16 thyroid cancer 29.9 AKT1 HOTAIR MALAT1 NEAT1 TP53
17 leukemia, acute myeloid 29.8 AKT1 HOTAIR MALAT1 TP53 TUG1 TUSC7
18 kidney cancer 29.8 HOTAIR MALAT1 TP53
19 glioblastoma 29.8 AKT1 HOTAIR MALAT1 RB1 TP53 TUG1
20 ovarian cancer 29.7 AKT1 CHEK2 HOTAIR MALAT1 MIR140 NEAT1
21 cervical cancer 29.6 AKT1 BCAR4 EWSAT1 HOTAIR MALAT1 NEAT1
22 hepatocellular carcinoma 29.6 AKT1 DANCR HOTAIR MALAT1 NEAT1 NNT-AS1
23 multifocal osteogenic sarcoma 12.4
24 telangiectatic osteogenic sarcoma 12.4
25 periosteal osteogenic sarcoma 12.4
26 small cell osteogenic sarcoma 12.4
27 kidney osteogenic sarcoma 12.4
28 synchronous multifocal osteogenic sarcoma 12.4
29 intracortical osteogenic sarcoma 12.3
30 adult extraosseous osteosarcoma 12.2
31 bone osteosarcoma 12.2
32 conventional central osteosarcoma 12.2
33 pediatric osteosarcoma 12.2
34 peripheral osteosarcoma 12.2
35 childhood parosteal osteogenic sarcoma 12.2
36 mediastinal osteogenic sarcoma 12.2
37 hepatic osteogenic sarcoma 12.2
38 asynchronous multifocal osteogenic sarcoma 12.2
39 childhood extraosseous osteosarcoma 12.1
40 osteosarcoma arising in bone paget's disease 12.0
41 childhood intracortical osteosarcoma 12.0
42 metachronous osteosarcoma of the bone 11.9
43 central nervous system osteosarcoma 11.9
44 oslam syndrome 11.8
45 bone cancer 11.8
46 juxtacortical osteosarcoma 11.5
47 sarcoma 11.4
48 li-fraumeni syndrome 11.3
49 rapadilino syndrome 11.3
50 hereditary multiple osteochondromas 11.3

Graphical network of the top 20 diseases related to Osteogenic Sarcoma:



Diseases related to Osteogenic Sarcoma

Symptoms & Phenotypes for Osteogenic Sarcoma

Symptoms via clinical synopsis from OMIM:

57
Lab:
osteogenic sarcoma
high alkaline phoshphatase
rearrangements involving chromosomes 13 and 14
loss of heterozygosity of chromosomes 13 and 17

Misc:
increased incidence in retinoblastoma cases
peak freqency in adolescence

Skel:
painful tender mass at long bone metaphysis

Radiology:
bone destruction and mineralized soft tissue mass


Clinical features from OMIM:

259500

Human phenotypes related to Osteogenic Sarcoma:

59 32 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 fever 59 32 very rare (1%) Very rare (<4-1%) HP:0001945
2 joint swelling 59 32 frequent (33%) Frequent (79-30%) HP:0001386
3 weight loss 59 32 very rare (1%) Very rare (<4-1%) HP:0001824
4 pathologic fracture 59 32 very rare (1%) Very rare (<4-1%) HP:0002756
5 pain 59 32 frequent (33%) Frequent (79-30%) HP:0012531
6 increased lactate dehydrogenase activity 59 32 frequent (33%) Frequent (79-30%) HP:0025435
7 osteolysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0002797
8 elevated alkaline phosphatase 59 32 frequent (33%) Frequent (79-30%) HP:0003155
9 abnormality of the femoral metaphysis 59 32 hallmark (90%) Very frequent (99-80%) HP:0006489
10 abnormality of the tibial metaphysis 59 32 frequent (33%) Frequent (79-30%) HP:0006491
11 abnormality of metabolism/homeostasis 32 HP:0001939
12 abnormality of the metaphysis 59 Frequent (79-30%)
13 retinoblastoma 32 HP:0009919
14 osteosarcoma 32 HP:0002669
15 abnormal lactate dehydrogenase activity 59 Frequent (79-30%)

Drugs & Therapeutics for Osteogenic Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008

Drugs for Osteogenic Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 342)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lithium carbonate Approved Phase 4 554-13-2
2
Heparin Approved, Investigational Phase 4,Not Applicable 9005-49-6 772 46507594
3
Dalteparin Approved Phase 4,Not Applicable 9005-49-6
4
Enoxaparin Approved Phase 4 9005-49-6 772
5
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
6 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
7 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
8 Analgesics, Non-Narcotic Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
9 Anti-Inflammatory Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
10 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
11 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
12 Central Nervous System Depressants Phase 4,Phase 3,Phase 1
13 Cyclooxygenase Inhibitors Phase 4,Phase 2,Not Applicable
14 Psychotropic Drugs Phase 4,Phase 1
15 Antimanic Agents Phase 4,Phase 1
16 Tranquilizing Agents Phase 4,Phase 1
17 Antidepressive Agents Phase 4
18 Fibrinolytic Agents Phase 4,Not Applicable
19 calcium heparin Phase 4,Not Applicable
20 Anticoagulants Phase 4,Not Applicable
21 Heparin, Low-Molecular-Weight Phase 4,Not Applicable
22 Antipyretics Phase 4
23 Platelet Aggregation Inhibitors Phase 4
24
Zoledronic acid Approved Phase 2, Phase 3,Phase 3,Phase 1 118072-93-8 68740
25
Ifosfamide Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 3778-73-2 3690
26
Cisplatin Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 15663-27-1 2767 441203 84093
27
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 23214-92-8 31703
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 1177-87-3
29
Gemcitabine Approved Phase 2, Phase 3,Phase 1,Not Applicable 95058-81-4 60750
30
Promethazine Approved, Investigational Phase 2, Phase 3 60-87-7 4927
31
Diphenhydramine Approved, Investigational Phase 2, Phase 3 147-24-0, 58-73-1 3100
32
Docetaxel Approved, Investigational Phase 2, Phase 3,Phase 1,Not Applicable 114977-28-5 148124
33
Dexamethasone Approved, Investigational, Vet_approved Phase 2, Phase 3,Phase 1 50-02-2 5743
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 6055-19-2, 50-18-0 2907
35
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 57-22-7, 2068-78-2 5978
36
Dactinomycin Approved, Investigational Phase 3,Phase 2,Not Applicable 50-76-0 457193 2019
37
Cobalt Approved, Experimental Phase 3,Phase 1,Phase 2 7440-48-4 104729
38
Mesna Approved, Investigational Phase 3,Phase 1,Phase 2,Not Applicable 3375-50-6 598
39
Etoposide Approved Phase 3,Phase 1,Phase 2,Not Applicable 33419-42-0 36462
40
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
41
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 4053 460612
42
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
43
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 59-05-2, 1959-05-2 126941
44
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
45
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
46
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
47
Irinotecan Approved, Investigational Phase 3,Phase 2,Phase 1 100286-90-6, 97682-44-5 60838
48
Trabectedin Approved, Investigational Phase 2, Phase 3 114899-77-3 108150
49
Sorafenib Approved, Investigational Phase 2, Phase 3,Phase 1 284461-73-0 216239 406563
50
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1

Interventional clinical trials:

(show top 50) (show all 465)
# Name Status NCT ID Phase Drugs
1 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
2 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
3 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
4 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
5 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
6 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
7 Osteosarcoma Study #2: A Randomized Trial of Pre-Surgical Chemotherapy vs. Immediate Surgery and Adjuvant Chemotherapy in the Treatment of Non-Metastatic Osteosarcoma. A Pediatric Oncology Group Phase III Study Completed NCT00001217 Phase 3 pre-surgical chemotherapy
8 Apatinib for Advanced Osteosarcoma After Failure of Standard Multimodal Therapy Completed NCT02711007 Phase 2, Phase 3 apatinib
9 Comparison of High-Dose Methotrexate (HDM) Plus Doxorubicin to HDM Plus Etoposide-Ifosfamide in Osteosarcoma Children Completed NCT00180908 Phase 3 Etoposide, Ifosfamide, Methotrexate;Doxorubicin, Methotrexate
10 Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma Completed NCT01176981 Phase 3 High Dose Methotrexate
11 Combination Chemotherapy and Surgery With or Without G-CSF in Treating Patients With Osteosarcoma Completed NCT00002539 Phase 3 cisplatin;doxorubicin hydrochloride
12 Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma Completed NCT00003937 Phase 3 cisplatin;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate
13 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
14 Sodium Thiosulfate in Preventing Hearing Loss in Young Patients Receiving Cisplatin for Newly Diagnosed Germ Cell Tumor, Hepatoblastoma, Medulloblastoma, Neuroblastoma, Osteosarcoma, or Other Malignancy Completed NCT00716976 Phase 3 sodium thiosulfate
15 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
16 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
17 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
18 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
19 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
20 ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma Recruiting NCT01459484 Phase 2, Phase 3 Mifamurtide arm
21 Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma Recruiting NCT01091883 Phase 3
22 Vigil + Irinotecan and Temozolomide in Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
23 Efficacy of Dose Intensification in Patients With Non-metastatic Ewing Sarcoma Recruiting NCT02063022 Phase 3 Standard treatment (as per protocol ISG SSG III);Intensified chemotherapy
24 Study in Localized and Disseminated Ewing Sarcoma Recruiting NCT00987636 Phase 3 Zoledronic acid;Busulfan;Treosulfan
25 Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma Recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Vincristine Sulfate
26 Combination Chemotherapy, PEG-Interferon Alfa-2b, and Surgery in Treating Patients With Osteosarcoma Active, not recruiting NCT00134030 Phase 3 Cisplatin;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Methotrexate
27 Randomized Controlled Trial to Assess Blockade of Voltage Gated Sodium Channels During Surgery in Operable Breast Cancer Active, not recruiting NCT01916317 Phase 3 0.5% lignocaine 60mM
28 Co-treatment With GnRH Analogs on the Ovarian Reserve in Young Women Treated With Alkylating Agents for Cancer Active, not recruiting NCT02856048 Phase 2, Phase 3 Triptorelin (GnRHa) + Chemotherapy
29 Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer Active, not recruiting NCT01987596 Phase 3
30 Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
31 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
32 Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma Terminated NCT00470223 Phase 3 cisplatin;doxorubicin hydrochloride;etoposide;ifosfamide;methotrexate;zoledronic acid
33 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
34 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
35 Enbrel Versus Placebo With Radiation Therapy to Combat Fatigue and Cachexia Terminated NCT00127387 Phase 2, Phase 3 Enbrel
36 Post-operative Radiotherapy in Poor Responders Ewing's Sarcoma Patients Withdrawn NCT01734863 Phase 3
37 Combination Chemotherapy With or Without Topotecan in Treating Patients With Newly Diagnosed Localized Ewing's Sarcoma Withdrawn NCT00334867 Phase 3 cyclophosphamide;dexrazoxane hydrochloride;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate
38 Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma Unknown status NCT01216826 Phase 2 Everolimus
39 A Study of Endostar Combined With Chemotherapy for Treatment of Osteosarcoma Unknown status NCT01002092 Phase 2 Chemotherapy;Endostar
40 Pilot Study of Curcumin Formulation and Ashwagandha Extract in Advanced Osteosarcoma Unknown status NCT00689195 Phase 1, Phase 2
41 Prospective Clinical Trial Evaluating Metronomic Chemotherapy in Patients With High-grade, Operable, Non-metastatic Osteosarcoma of the Extremity Unknown status NCT02273583 Phase 2 continuous oral cyclophosphamide and methotrexate
42 Interferon Alfa and Thalidomide in Treating Patients With Soft Tissue Sarcoma or Bone Sarcoma Unknown status NCT00026416 Phase 2 thalidomide
43 Pilot Study of Expanded , Activated Haploidentical Natural Killer Cell Infusions for Sarcomas Unknown status NCT02409576 Phase 1, Phase 2
44 Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy Unknown status NCT00807261 Phase 2 Gemcitabine and Docetaxel
45 Study of Vinorelbine and Cyclofosfamide Among Patients With Refractory Tumours or in Relapse Unknown status NCT00180947 Phase 2 Vinorelbine, cyclofosfamide
46 The Adoptive Immunotherapy for Solid Tumors Using Modified Autologous Cytokine-induced Killer Cells Unknown status NCT01868490 Phase 1, Phase 2 cytokine induced killer cells
47 Hematopoietic Stem Cell Transplantation From Human Leukocyte Antigen (HLA) Compatible Donor in Ewing Sarcomas and Soft Tissues Sarcomas Unknown status NCT00998361 Phase 2
48 Tandem Peripheral Blood Stem Cell (PBSC) Rescue for High Risk Solid Tumors Unknown status NCT00179816 Phase 1, Phase 2 High-Dose Chemotherapy with Tandem PBSC Rescue.
49 Trial With Gemcitabine and Rapamycin in Second Line of Metastatic Osteosarcoma Completed NCT02429973 Phase 2 Gemcitabine plus rapamycin
50 A Eurosarc Study of Mifamurtide in Advanced Osteosarcoma (MEMOS) Completed NCT02441309 Phase 2 Mifamurtide;Ifosfamide

Search NIH Clinical Center for Osteogenic Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: osteosarcoma

Genetic Tests for Osteogenic Sarcoma

Genetic tests related to Osteogenic Sarcoma:

# Genetic test Affiliating Genes
1 Osteosarcoma 29 CHEK2 RB1 TP53

Anatomical Context for Osteogenic Sarcoma

MalaCards organs/tissues related to Osteogenic Sarcoma:

41
Bone, Lung, Breast, Testes, T Cells, Bone Marrow, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Osteogenic Sarcoma:

19
Bone

Publications for Osteogenic Sarcoma

Articles related to Osteogenic Sarcoma:

(show top 50) (show all 1985)
# Title Authors Year
1
Hsa-let-7g promotes osteosarcoma by reducing HOXB1 to activate NF-kB pathway. ( 30551492 )
2019
2
ELK1-induced upregulation of long non-coding RNA MIR100HG predicts poor prognosis and promotes the progression of osteosarcoma by epigenetically silencing LATS1 and LATS2. ( 30551532 )
2019
3
Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. ( 30343113 )
2019
4
Knockdown of MALAT1 inhibits osteosarcoma progression via regulating the miR‑34a/cyclin D1 axis. ( 30365098 )
2019
5
SND1 promotes the proliferation of osteosarcoma cells by upregulating COX‑2/PGE2 expression via activation of NF‑κB. ( 30365124 )
2019
6
Parosteal osteosarcoma with focal fatty metaplasia: A case report. ( 30425774 )
2019
7
LPS promote Osteosarcoma invasion and migration through TLR4/HOTAIR. ( 30240881 )
2019
8
Blood-borne biomarkers of osteosarcoma: A systematic review. ( 30251311 )
2019
9
Factors influencing survival after recurrence in osteosarcoma: A report from the Children's Oncology Group. ( 30255612 )
2019
10
Prolonged response to sorafenib in a patient with refractory metastatic osteosarcoma and a somatic PDGFRA D846V mutation. ( 30318721 )
2019
11
Imaging the interaction of αv integrin-GFP in osteosarcoma cells with RFP-expressing host stromal cells and tumor-scaffold collagen in the primary and metastatic tumor microenvironment. ( 30145815 )
2019
12
Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma. ( 29964327 )
2019
13
Fluorescent In Situ Hybridization for TP53 in the Diagnosis of Pediatric Osteogenic Sarcoma. ( 29543677 )
2018
14
Simultaneous osteosarcoma and adenocarcinoma of the gallbladder: A rare case report and literature review. ( 30460899 )
2018
15
Malignant Transformation of Testicular Teratoma to PNET, Adenocarcinoma, and Osteosarcoma with Complete Remission after Surgery and Combination Chemotherapy in a Young Adult Male. ( 30402315 )
2018
16
Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin. ( 30288129 )
2018
17
Sequence analysis of cell-free DNA derived from cultured human bone osteosarcoma (143B) cells. ( 30261820 )
2018
18
Bone metastasis from cholangiocarcinoma mimicking osteosarcoma: A case report and review literature. ( 30402235 )
2018
19
Chondroblastic osteosarcoma of the middle ear in a guinea pig (Cavia porcellus). ( 30104775 )
2018
20
Prognostic factors to survival of patients with chondroblastic osteosarcoma. ( 30278586 )
2018
21
Spontaneous Conventional Osteosarcoma Transformation of a Chondroblastoma: A Case Report and Literature Review. ( 30532312 )
2018
22
Spontaneous Conventional Osteosarcoma Transformation of a Chondroblastoma: A Case Report and Literature Review. ( 29416176 )
2018
23
Osteogenic Sarcoma in an Adolescent With Cystic Fibrosis: Successful Treatment Despite Significant Obstacles. ( 30298123 )
2018
24
Increased risk of colon cancer and osteogenic sarcoma in Diamond-Blackfan anemia. ( 30266775 )
2018
25
Successful Treatment of Osteosarcoma Without Methotrexate in a 13-Year-Old Boy With Down Syndrome. ( 29750745 )
2018
26
Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children's Oncology Group. ( 30131550 )
2018
27
Whole Lung Irradiation in Patients with Osteosarcoma and Ewing Sarcoma. ( 30194141 )
2018
28
Maternally expressed, paternally imprinted, embryonic non-coding RNA are expressed in osteosarcoma, Ewing sarcoma and spindle cell sarcoma. ( 30497804 )
2018
29
Uncoupling Warburg effect and stemness in CD133+ve cancer stem cells from Saos-2 (osteosarcoma) cell line under hypoxia. ( 30128626 )
2018
30
Osteosarcoma in an Adolescent with Kniest Dysplasia: A Case Report. ( 30303846 )
2018
31
Population Pharmacokinetic Study and Individual Dose Adjustments of High-Dose Methotrexate in Chinese Pediatric Patients With Acute Lymphoblastic Leukemia or Osteosarcoma. ( 30556906 )
2018
32
Modeling Osteosarcoma Using Li-Fraumeni Syndrome Patient-derived Induced Pluripotent Stem Cells. ( 29985349 )
2018
33
Lymphocyte-monocyte ratio at day 14 of first cisplatin-doxorubicin chemotherapy is associated with treatment outcome of pediatric patients with localized osteosarcoma. ( 30304898 )
2018
34
Antitumor effects of SB injection in canine osteosarcoma and melanoma cell lines. ( 30382494 )
2018
35
Characteristics and predictors for secondary leukemia and myelodysplastic syndrome in Ewing and osteosarcoma survivors. ( 30165126 )
2018
36
Osteoblastoma-like osteosarcoma: high-grade or low-grade osteosarcoma? ( 30152881 )
2018
37
Osteoblastic Osteosarcoma Arising beneath an Osteochondroma in an 11-Year-Old Male with Multiple Hereditary Exostoses. ( 30123601 )
2018
38
Osteogenic sarcoma of the skull: long-term outcome of a rare tumor. ( 30120533 )
2018
39
Primary osteogenic sarcoma of the skull: Report of two cases with review of literature. ( 30264740 )
2018
40
Two HLA Class II Gene Variants Are Independently Associated with Pediatric Osteosarcoma Risk. ( 30038050 )
2018
41
Clinically relevant concentration of anti-viral drug ribavirin selectively targets pediatric osteosarcoma and increases chemosensitivity. ( 30454696 )
2018
42
Simultaneous Bilateral Spontaneous Pneumothorax: A Rare Complication of Osteosarcoma. ( 30087821 )
2018
43
Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. ( 30208204 )
2018
44
Validity and completeness of the Scandinavian Sarcoma Group Central Register by comparison with a nationwide cohort of patients with osteosarcoma in Norway. ( 30208205 )
2018
45
Disappearing hemipelvis: Low grade osteosarcoma, an unusual and poorly described variant of Paget's Sarcoma. ( 29881196 )
2018
46
A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial. ( 29791011 )
2018
47
Patients with osteosarcoma and soft tissue sarcoma might become "cancer refugees" in some Japanese regional cities. ( 29497333 )
2018
48
Metastatic tumor cells detection and anti-metastatic potential with vesicular stomatitis virus in immunocompetent murine model of osteosarcoma. ( 29637599 )
2018
49
Novel Germline PTEN Mutation Associated with Cowden Syndrome and Osteosarcoma. ( 29496690 )
2018
50
Treating Osteosarcoma with CAR T cells. ( 30549299 )
2018

Variations for Osteogenic Sarcoma

ClinVar genetic disease variations for Osteogenic Sarcoma:

6 (show all 41)
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.254C> T (p.Pro85Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs17883862 GRCh37 Chromosome 22, 29130456: 29130456
2 CHEK2 NM_007194.3(CHEK2): c.254C> T (p.Pro85Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs17883862 GRCh38 Chromosome 22, 28734468: 28734468
3 CHEK2 NM_007194.3(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh37 Chromosome 22, 29130661: 29130661
4 CHEK2 NM_007194.3(CHEK2): c.49G> T (p.Ala17Ser) single nucleotide variant Pathogenic rs137853008 GRCh38 Chromosome 22, 28734673: 28734673
5 CHEK2 NM_007194.4(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh37 Chromosome 22, 29091207: 29091207
6 CHEK2 NM_007194.4(CHEK2): c.1283C> T (p.Ser428Phe) single nucleotide variant risk factor rs137853011 GRCh38 Chromosome 22, 28695219: 28695219
7 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh37 Chromosome 17, 7577559: 7577559
8 TP53 NM_000546.5(TP53): c.722C> T (p.Ser241Phe) single nucleotide variant Likely pathogenic rs28934573 GRCh38 Chromosome 17, 7674241: 7674241
9 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
10 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh38 Chromosome 17, 7673802: 7673802
11 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh38 Chromosome 17, 7675131: 7675137
12 TP53 NM_000546.5(TP53): c.475_481dupGCCATGG (p.Ala161Glyfs) duplication Pathogenic rs863223301 GRCh37 Chromosome 17, 7578449: 7578455
13 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
14 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh38 Chromosome 14, 104780214: 104780214
15 CHEK2 NM_007194.3(CHEK2): c.1336A> G (p.Asn446Asp) single nucleotide variant Uncertain significance rs121908705 GRCh37 Chromosome 22, 29091154: 29091154
16 CHEK2 NM_007194.3(CHEK2): c.1336A> G (p.Asn446Asp) single nucleotide variant Uncertain significance rs121908705 GRCh38 Chromosome 22, 28695166: 28695166
17 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
18 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869
19 CHEK2 NM_007194.4(CHEK2): c.1270T> C (p.Tyr424His) single nucleotide variant Conflicting interpretations of pathogenicity rs139366548 GRCh37 Chromosome 22, 29091220: 29091220
20 CHEK2 NM_007194.4(CHEK2): c.1270T> C (p.Tyr424His) single nucleotide variant Conflicting interpretations of pathogenicity rs139366548 GRCh38 Chromosome 22, 28695232: 28695232
21 CHEK2 NM_007194.4(CHEK2): c.1312G> T (p.Asp438Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs200050883 GRCh37 Chromosome 22, 29091178: 29091178
22 CHEK2 NM_007194.4(CHEK2): c.1312G> T (p.Asp438Tyr) single nucleotide variant Conflicting interpretations of pathogenicity rs200050883 GRCh38 Chromosome 22, 28695190: 28695190
23 CHEK2 NM_007194.4(CHEK2): c.1556G> T (p.Arg519Leu) single nucleotide variant Uncertain significance rs587780180 GRCh37 Chromosome 22, 29083961: 29083961
24 CHEK2 NM_007194.4(CHEK2): c.1556G> T (p.Arg519Leu) single nucleotide variant Uncertain significance rs587780180 GRCh38 Chromosome 22, 28687973: 28687973
25 CHEK2 NM_007194.3(CHEK2): c.980A> G (p.Tyr327Cys) single nucleotide variant Uncertain significance rs587780194 GRCh37 Chromosome 22, 29095854: 29095854
26 CHEK2 NM_007194.3(CHEK2): c.980A> G (p.Tyr327Cys) single nucleotide variant Uncertain significance rs587780194 GRCh38 Chromosome 22, 28699866: 28699866
27 ERCC2 NM_000400.3(ERCC2): c.2251A> C (p.Lys751Gln) single nucleotide variant Benign rs13181 GRCh37 Chromosome 19, 45854919: 45854919
28 ERCC2 NM_000400.3(ERCC2): c.2251A> C (p.Lys751Gln) single nucleotide variant Benign rs13181 GRCh38 Chromosome 19, 45351661: 45351661
29 CHEK2 NM_007194.3(CHEK2): c.1451C> T (p.Pro484Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs564605612 GRCh37 Chromosome 22, 29090030: 29090030
30 CHEK2 NM_007194.3(CHEK2): c.1451C> T (p.Pro484Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs564605612 GRCh38 Chromosome 22, 28694042: 28694042
31 CHEK2 NM_007194.3(CHEK2): c.556A> C (p.Asn186His) single nucleotide variant Conflicting interpretations of pathogenicity rs146198085 GRCh37 Chromosome 22, 29121001: 29121001
32 CHEK2 NM_007194.3(CHEK2): c.556A> C (p.Asn186His) single nucleotide variant Conflicting interpretations of pathogenicity rs146198085 GRCh38 Chromosome 22, 28725013: 28725013
33 CHEK2 NM_007194.4(CHEK2): c.319+2T> A single nucleotide variant Likely pathogenic rs587782401 GRCh37 Chromosome 22, 29130389: 29130389
34 CHEK2 NM_007194.4(CHEK2): c.319+2T> A single nucleotide variant Likely pathogenic rs587782401 GRCh38 Chromosome 22, 28734401: 28734401
35 CHEK2 NM_007194.4(CHEK2): c.1216C> T (p.Arg406Cys) single nucleotide variant Uncertain significance rs587782527 GRCh37 Chromosome 22, 29091741: 29091741
36 CHEK2 NM_007194.4(CHEK2): c.1216C> T (p.Arg406Cys) single nucleotide variant Uncertain significance rs587782527 GRCh38 Chromosome 22, 28695753: 28695753
37 TP53 NM_000546.5(TP53): c.1024C> T (p.Arg342Ter) single nucleotide variant Pathogenic rs730882029 GRCh38 Chromosome 17, 7670685: 7670685
38 TP53 NM_000546.5(TP53): c.1024C> T (p.Arg342Ter) single nucleotide variant Pathogenic rs730882029 GRCh37 Chromosome 17, 7574003: 7574003
39 CHEK2 NM_007194.3(CHEK2): c.170C> T (p.Ser57Phe) single nucleotide variant Uncertain significance rs730881695 GRCh38 Chromosome 22, 28734552: 28734552
40 CHEK2 NM_007194.3(CHEK2): c.170C> T (p.Ser57Phe) single nucleotide variant Uncertain significance rs730881695 GRCh37 Chromosome 22, 29130540: 29130540
41 TSC2 NM_000548.4(TSC2): c.2764_2765delTT (p.Leu922Valfs) deletion Likely pathogenic GRCh38 Chromosome 16, 2076512: 2076513

Cosmic variations for Osteogenic Sarcoma:

9 (show all 21)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6921292 SMARCA4 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 16
2 COSM866 RB1 bone,NS,osteosarcoma,osteoblastic c.1399C>T p.R467* 13:48380062-48380062 16
3 COSM6921291 bone,NS,osteosarcoma,osteoblastic c.2728A>G p.T910A 19:11021836-11021836 16
4 COSM6912846 RYBP bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 15
5 COSM2804274 RPTOR bone,NS,osteosarcoma,chondroblastic c.2911G>A p.V971I 17:80925472-80925472 15
6 COSM1034 RB1 bone,NS,osteosarcoma,chondroblastic c.1499-1G>T p.? 13:48381246-48381246 15
7 COSM6932882 PTCH1 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 15
8 COSM6912848 PIK3CB bone,NS,osteosarcoma,chondroblastic c.1064C>G p.A355G 3:138714706-138714706 15
9 COSM302646 KMT2D bone,NS,osteosarcoma,chondroblastic c.15208C>T p.R5070* 12:49024612-49024612 15
10 COSM4591270 KMT2C bone,NS,osteosarcoma,chondroblastic c.2512G>A p.G838S 7:152247922-152247922 15
11 COSM1179669 KMT2C bone,NS,osteosarcoma,chondroblastic c.943G>A p.G315S 7:152273774-152273774 15
12 COSM6506545 KMT2C bone,NS,osteosarcoma,chondroblastic c.2468T>C p.I823T 7:152247966-152247966 15
13 COSM27895 GNAS bone,NS,osteosarcoma,parosteal c.602G>A p.R201H 20:58909366-58909366 15
14 COSM27887 GNAS bone,NS,osteosarcoma,parosteal c.601C>T p.R201C 20:58909365-58909365 15
15 COSM6914869 APC bone,NS,osteosarcoma,chondroblastic c.6517A>G p.K2173E 5:112842111-112842111 15
16 COSM6932881 bone,NS,osteosarcoma,chondroblastic c.2183C>T p.T728M 9:95468818-95468818 15
17 COSM6932883 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 15
18 COSM123397 bone,NS,osteosarcoma,chondroblastic c.2530C>T p.R844C 20:58909365-58909365 15
19 COSM6912847 bone,NS,osteosarcoma,chondroblastic c.699+1G>A p.? 3:72379039-72379039 15
20 COSM6932884 bone,NS,osteosarcoma,chondroblastic c.2180C>T p.T727M 9:95468818-95468818 15
21 COSM302647 bone,NS,osteosarcoma,chondroblastic c.16018C>T p.R5340* 12:49024612-49024612 15

Copy number variations for Osteogenic Sarcoma from CNVD:

7 (show top 50) (show all 688)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 17390 1 142600000 150300000 Gain Osteosarcoma
2 17391 1 142600000 155000000 Amplification Osteosarcoma
3 39243 10 112373403 112374403 Gain Osteosarcoma
4 39244 10 112373452 112374452 Loss Osteosarcoma
5 41292 10 15522819 15523819 Loss Osteosarcoma
6 41294 10 15581536 15582536 Loss Osteosarcoma
7 46318 10 80680600 80681600 Loss Osteosarcoma
8 46347 10 80806585 80807585 Loss Osteosarcoma
9 58796 11 69623478 69623778 Gain Osteosarcoma
10 58827 11 69805619 69805919 Loss Osteosarcoma
11 60316 11 85062165 85063165 Gain Osteosarcoma
12 60323 11 85134471 85135471 Gain Osteosarcoma
13 62537 12 10955611 10956611 Gain Osteosarcoma
14 62568 12 10980072 10981072 Gain Osteosarcoma
15 62603 12 11027103 11028103 Loss Osteosarcoma
16 63038 12 11366981 11367981 Gain Osteosarcoma
17 63258 12 11668570 11669570 Gain Osteosarcoma
18 63272 12 11686468 11687468 Loss Osteosarcoma
19 64267 12 12569624 12570624 Loss Osteosarcoma
20 64268 12 12573054 12574054 Loss Osteosarcoma
21 64280 12 12586928 12587928 Gain Osteosarcoma
22 64287 12 12597865 12598865 Loss Osteosarcoma
23 64343 12 12687540 12688540 Gain Osteosarcoma
24 64577 12 12982393 12983393 Gain Osteosarcoma
25 64986 12 14117741 14118741 Loss Osteosarcoma
26 64996 12 14185562 14186562 Gain Osteosarcoma
27 64998 12 14245323 14246323 Gain Osteosarcoma
28 65344 12 16046949 16047949 Gain Osteosarcoma
29 65345 12 16049923 16050923 Loss Osteosarcoma
30 65347 12 16051037 16052037 Gain Osteosarcoma
31 65348 12 16051062 16052062 Loss Osteosarcoma
32 65349 12 16054806 16055806 Gain Osteosarcoma
33 65384 12 16430865 16431865 Gain Osteosarcoma
34 65385 12 16433142 16434142 Loss Osteosarcoma
35 65386 12 16436484 16437484 Gain Osteosarcoma
36 65391 12 16463017 16464017 Gain Osteosarcoma
37 65392 12 16466398 16467398 Gain Osteosarcoma
38 65400 12 16603247 16604247 Loss Osteosarcoma
39 65436 12 17462418 17463418 Gain Osteosarcoma
40 65437 12 17462804 17463804 Loss Osteosarcoma
41 65493 12 1815281 1816281 Loss Osteosarcoma
42 65649 12 20337069 20338069 Gain Osteosarcoma
43 65959 12 23459482 23460482 Loss Osteosarcoma
44 65979 12 23822360 23823360 Loss Osteosarcoma
45 66478 12 29963884 29964884 Loss Osteosarcoma
46 66480 12 29986214 29987214 Gain Osteosarcoma
47 66482 12 30002256 30003256 Loss Osteosarcoma
48 66483 12 30014548 30015548 Loss Osteosarcoma
49 66485 12 30029899 30030899 Loss Osteosarcoma
50 67171 12 37173408 37174408 Loss Osteosarcoma

Expression for Osteogenic Sarcoma

Search GEO for disease gene expression data for Osteogenic Sarcoma.

Pathways for Osteogenic Sarcoma

GO Terms for Osteogenic Sarcoma

Cellular components related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 PML body GO:0016605 8.8 CHEK2 RB1 TP53

Biological processes related to Osteogenic Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.8 AKT1 CHEK2 RB1 SOX4 TP53
2 striated muscle cell differentiation GO:0051146 9.37 AKT1 RB1
3 regulation of signal transduction by p53 class mediator GO:1901796 9.33 AKT1 CHEK2 TP53
4 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.32 CHEK2 TP53
5 replicative senescence GO:0090399 9.26 CHEK2 TP53
6 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.13 CHEK2 SOX4 TP53
7 cellular response to hypoxia GO:0071456 8.92 AKT1 MALAT1 MIR140 TP53

Sources for Osteogenic Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....